Repare Therapeutics (NASDAQ:RPTX) Earns "Buy" Rating from HC Wainwright

Repare Therapeutics (NASDAQ:RPTX - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright's price objective points to a potential upside of 178.55% from the stock's current price.

Separately, Lifesci Capital raised shares of Repare Therapeutics to a "strong-buy" rating in a research report on Monday, July 29th.

Repare Therapeutics Trading Up 2.9 %

Repare Therapeutics stock traded up $0.10 during mid-day trading on Friday, reaching $3.59. The company's stock had a trading volume of 70,872 shares, compared to its average volume of 162,200. Repare Therapeutics has a twelve month low of $2.71 and a twelve month high of $8.49. The business has a 50 day moving average price of $3.34 and a 200-day moving average price of $3.39. The firm has a market cap of $152.40 million, a price-to-earnings ratio of -2.19 and a beta of 0.72.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.03. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%. The company had revenue of $1.07 million for the quarter, compared to the consensus estimate of $4.02 million. On average, equities analysts expect that Repare Therapeutics will post -2.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Repare Therapeutics

Large investors have recently made changes to their positions in the business. Vontobel Holding Ltd. boosted its position in shares of Repare Therapeutics by 20.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company's stock valued at $83,000 after acquiring an additional 4,000 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company's stock worth $174,000 after acquiring an additional 8,809 shares during the last quarter. Blue Owl Capital Holdings LP raised its holdings in shares of Repare Therapeutics by 8.0% during the second quarter. Blue Owl Capital Holdings LP now owns 3,372,499 shares of the company's stock valued at $11,129,000 after acquiring an additional 250,000 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Repare Therapeutics by 428.4% during the 2nd quarter. Squarepoint Ops LLC now owns 142,974 shares of the company's stock worth $472,000 after acquiring an additional 115,916 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Repare Therapeutics during the second quarter valued at approximately $273,000. 85.09% of the stock is owned by hedge funds and other institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.